IRVINE, Calif., May 15, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Wins Finance Holdings Inc. (“Wins” or the “Company”) (Nasdaq:WINS). Investors who purchased or otherwise acquired shares between October 29, 2015 through March 29, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 5, 2017 lead plaintiff motion deadline.
If you purchased the Company’s shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that through the Class Period, Wins issued materially false and misleading statements regarding its projected earnings, valuation, and future business operations, which artificially inflated its securities prices. It is alleged that the Company falsely stated it maintained a U.S. headquarters in order to gain inclusion on the Russell indices when its headquarters are actually located in China, among other market manipulations during the Class Period. On March 30, 2017, SeekingAlpha.com published an article stating that the U.S. Securities & Exchange Commission is investigating Wins for alleged “market manipulation.” When this information was released, the stock price of Wins declined materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



